Does comorbid disease burden predict adverse outcomes in high-risk patients treated with TAVR?
341 patients treated with transcatheter aortic valve replacement (TAVR) from January 2015 to October 2018, mean age 81.4 (SD 8.0) years, mean Society of Thoracic Surgeons predicted risk of mortality score of 6.7% (SD 4.8).
Transcatheter aortic valve replacement (TAVR)
30-day rehospitalizations, composite of 30-day rehospitalization and 30-day mortality, and 1-year mortalityhard clinical
Comorbid disease burden is associated with worse clinical outcomes after TAVR and is not adequately captured by standard risk assessment tools like the STS score.
Background Transcatheter aortic valve replacement (TAVR) has become the preferred treatment for symptomatic patients with aortic stenosis and elevated procedural risk. Many deaths following TAVR are because of noncardiac causes and comorbid disease burden may be a major determinant of postprocedure outcomes. The prevalence of comorbid conditions and associations with outcomes after TAVR has not been studied. Methods and Results This was a retrospective single-center study of patients treated with TAVR from January 2015 to October 2018. The association between 21 chronic conditions and short- and medium-term outcomes was assessed. A total of 341 patients underwent TAVR and had 1-year follow-up. The mean age was 81.4 (SD 8.0) years with a mean Society of Thoracic Surgeons predicted risk of mortality score of 6.7% (SD 4.8). Two hundred twenty (65%) patients had ≥4 chronic conditions present at the time of TAVR. There was modest correlation between Society of Thoracic Surgeons predicted risk of mortality and comorbid disease burden (r=0.32, P<0.001). After adjusting for Society of Thoracic Surgeons predicted risk of mortality, age, and vascular access, each additional comorbid condition was associated with increased rates of 30-day rehospitalizations (odds ratio, 1.21; 95% CI, 1.02-1.44), a composite of 30-day rehospitalization and 30-day mortality (odds ratio, 1.20; 95% CI, 1.02-1.42), and 1-year mortality (odds ratio, 1.29; 95% CI, 1.05-1.59). Conclusions Comorbid disease burden is associated with worse clinical outcomes in high-risk patients treated with TAVR. The risks associated with comorbid disease burden are not adequately captured by standard risk assessment. A systematic assessment of comorbid conditions may improve risk stratification efforts.
Building similarity graph...
Analyzing shared references across papers
Loading...
Daniel R. Feldman
Mikhail Romashko
Benjamin Koethe
Journal of the American Heart Association
SHILAP Revista de lepidopterología
University of Maryland, Baltimore
Tufts Medical Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Feldman et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d775b7db9d5e1bf4b8ac30 — DOI: https://doi.org/10.1161/jaha.120.018978